New HIV pill combo tested for rapid virus control in treatment-naive patients
NCT ID NCT07357584
First seen Jan 27, 2026 · Last updated May 21, 2026 · Updated 19 times
Summary
This study tests a three-drug pill (doravirine, lamivudine, tenofovir) for people newly diagnosed with HIV who have never taken HIV medications. The goal is to see if starting this treatment quickly can suppress the virus to undetectable levels by 48 weeks. About 100 adults will take the pill daily, and researchers will monitor viral load and safety. This is a disease control study because HIV requires lifelong medication.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fundacion Huesped
Buenos Aires, C1202ABB, Argentina
-
Fundacion IDEAA -Infectologia de atencion ambulatoria
Ciudad Autonoma de Buenos Aire, Buenos Aires, C1405CKC, Argentina
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.